Version May 2024
| Native TEG |
| Measures clot formation in the absence of a specific activator in either untreated whole blood or in citrated whole blood after recalcification. |
| Rapid-TEG (rTEG) |
| Tissue factor is used as the activator inducing clot formation via the extrinsic pathway. Compared with native TEG, rTEG gives a readout of clot characteristics within about 10 minutes. The corresponding RoTEM test is the EXTEM. |
| Kaolin-TEG |
| Phospholipid and kaolin are used to induce activation via the intrinsic pathway. The corresponding RoTEM test is the INTEM, which uses phospholipid and ellagic acid as activators. |
| Heparinase treatment |
| Simultaneous measurements can be performed comparing heparinase-treated blood with untreated blood to identify the effects of endogenous heparan sulfates, exogenous heparin, and heparinoids. The corresponding RoTEM assay is the HEPTEM. |
| Platelet mapping |
| Platelet mapping assesses platelet function via the cyclooxygenase and ADP/P2 signaling pathways. The decrement in MA can be measured in the presence of platelet antagonists such as acetylsalicylic acid, dipyridamole, and clopidogrel and compared with the untreated MA. |
| Fibrin function testing |
| The RoTEM FIBTEM test activates the extrinsic pathway in the presence of cytochalasin D, which is a cytoskeletal inhibitor of platelet activity. This test qualitatively assesses fibrinogen levels since the clot formation in this test is attributable to fibrin polymerization alone. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
